www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/11817

Title: IMPACT OF MAMMAPRINT ON THE ROUTINE TREATMENT DECISION MAKING PROCESS IN AN UNSELECTED EARLY BREAST CANCER PATIENT POPULATION IN BELGIUM
Authors: Cusumano, P. G.
Liebens, F.
Carly, B.
Jerusalem, G.
Lifrange, E.
JANSSENS, Jaak
VLASSELAER, J.
Jossa, V.
Issue Date: 2010
Publisher: OXFORD UNIV PRESS
Citation: ANNALS OF ONCOLOGY, 21. p. 86-87
Abstract: Background: Multidisciplinary teams nowadays decide on oncological adjuvant treatments by using common clinical and biological criteria. Differences in the quality of IHC analysis and medical board interpretation of prognostic and predictive factors can substantially affect the adjuvant strategy resulting in risks for under- and overtreatment. The main objective of this study is to compare decisions taken when diagnostic gene expression analysis (70-gene MammaPrint assay)(MP) is added prospectively, to the traditional treatment decision making process in an unselected patient. Methods: In 2009, we collected fresh tumour samples during surgery in 162 breast cancer patients. Sufficient RNA for microarray analysis was obtained from 135 patients. MammaPrint low risk (MP LR) profiles were found in 42% MammaPrint high risk (MP HR) profiles in 58% of the patients. Following conventional treatment recommendations, 11 of 57 (19%) MP LR patients received chemotherapy and 34 of 78 (44%) MP HR patients received no chemotherapy. The MP HR patients receiving no chemotherapy (CT) and MP LR patients receiving CT were considered unmatched cases and submitted for second opinion to three independent academic teams initially blinded and subsequently unblinded for the MP. Results: According to the initial recommendation (blinded for MP) of these 3 academic teams, 13 of 34 MP HR patients remained without CT and 9 of 11 MP LR patients would still receive chemotherapy. Subsequently, unblinded for the MammaPrint result, these 3 academic teams changed their recommendation in 6 of 13 MP HR patients. Ultimately, from the 78 patients classified as High risk by MammaPrint, 7 remained without chemotherapy treatment recommendation in this multidisciplinary adjuvant treatment planning(9%). Conclusions: This study demonstrates high variability in the adjuvant strategies between multidisciplinary teams based on traditional patient and tumour related parameters. In our study population, the MammaPrint gene profile would have modified adjuvant treatment recommendation in at least 10% of patients.
Notes: [Cusumano, P. G.; Jossa, V.] CHC Liege, Breast Unit, Liege, Belgium. [Liebens, F.; Carly, B.] CHU St Pierre, Breast Unit, Brussels, Belgium. [Jerusalem, G.; Lifrange, E.] CHU Liege, Liege, Belgium. [Janssens, J.; Vlasselaer, J.] Univ Hasselt, Hasselt, Belgium.
URI: http://hdl.handle.net/1942/11817
ISI #: 000283115900258
ISSN: 0923-7534
Category: M
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.